Taiwan
· Delayed Price · Currency is TWD Golden Biotechnology Statistics
Total Valuation
Golden Biotechnology has a market cap or net worth of TWD 2.73 billion. The enterprise value is 2.95 billion.
| Market Cap | 2.73B |
| Enterprise Value | 2.95B |
Important Dates
The next estimated earnings date is Monday, April 28, 2025.
| Earnings Date | Apr 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Golden Biotechnology has 162.23 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 162.23M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 13.35% |
| Owned by Institutions (%) | 0.13% |
| Float | 140.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 41.68 |
| PB Ratio | 9.96 |
| P/TBV Ratio | 12.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.77 |
| EV / Sales | 51.28 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -11.70 |
Financial Position
The company has a current ratio of 0.65, with a Debt / Equity ratio of 1.26.
| Current Ratio | 0.65 |
| Quick Ratio | 0.31 |
| Debt / Equity | 1.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.21 |
| Interest Coverage | -55.39 |
Financial Efficiency
Return on equity (ROE) is -88.08% and return on invested capital (ROIC) is -32.56%.
| Return on Equity (ROE) | -88.08% |
| Return on Assets (ROA) | -31.08% |
| Return on Capital (ROIC) | -32.56% |
| Revenue Per Employee | 471,246 |
| Profits Per Employee | -3.11M |
| Employee Count | 122 |
| Asset Turnover | 0.08 |
| Inventory Turnover | 0.71 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.92% in the last 52 weeks. The beta is 1.05, so Golden Biotechnology's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | -52.92% |
| 50-Day Moving Average | 16.61 |
| 200-Day Moving Average | 20.77 |
| Relative Strength Index (RSI) | 47.37 |
| Average Volume (20 Days) | 438,147 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Golden Biotechnology had revenue of TWD 57.49 million and -379.32 million in losses. Loss per share was -2.67.
| Revenue | 57.49M |
| Gross Profit | 2.10M |
| Operating Income | -376.23M |
| Pretax Income | -379.02M |
| Net Income | -379.32M |
| EBITDA | -345.84M |
| EBIT | -376.23M |
| Loss Per Share | -2.67 |
Balance Sheet
The company has 89.36 million in cash and 304.07 million in debt, giving a net cash position of -214.71 million or -1.32 per share.
| Cash & Cash Equivalents | 89.36M |
| Total Debt | 304.07M |
| Net Cash | -214.71M |
| Net Cash Per Share | -1.32 |
| Equity (Book Value) | 240.72M |
| Book Value Per Share | 1.69 |
| Working Capital | -106.43M |
Cash Flow
In the last 12 months, operating cash flow was -251.09 million and capital expenditures -826,000, giving a free cash flow of -251.92 million.
| Operating Cash Flow | -251.09M |
| Capital Expenditures | -826,000 |
| Free Cash Flow | -251.92M |
| FCF Per Share | -1.55 |
Margins
| Gross Margin | 3.65% |
| Operating Margin | -654.40% |
| Pretax Margin | -659.26% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Golden Biotechnology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -15.83% |
| FCF Yield | -9.22% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Golden Biotechnology has an Altman Z-Score of 4.28.
| Altman Z-Score | 4.28 |
| Piotroski F-Score | n/a |